

Tadahiro Shoji

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6712896/publications.pdf>

Version: 2024-02-01

39
papers

452
citations

687363

13
h-index

752698

20
g-index

40
all docs

40
docs citations

40
times ranked

779
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2335.	4.1	52
2	Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary. <i>International Journal of Clinical Oncology</i> , 2015, 20, 967-973.	2.2	40
3	Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 2-10.	2.5	37
4	Immunotherapy for Uterine Cervical Cancer. <i>Healthcare (Switzerland)</i> , 2019, 7, 108.	2.0	29
5	Analysis of prognostic factors for patients with bulky squamous cell carcinoma of the uterine cervix who underwent neoadjuvant chemotherapy followed by radical hysterectomy. <i>International Journal of Clinical Oncology</i> , 2015, 20, 345-350.	2.2	27
6	Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 657-662.	2.3	26
7	Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix. <i>International Journal of Clinical Oncology</i> , 2016, 21, 1128-1135.	2.2	22
8	Clinical Significance of Atypical Glandular Cells in the Bethesda System 2001: A Comparison with the Histopathological Diagnosis of Surgically Resected Specimens. <i>Cancer Investigation</i> , 2014, 32, 105-109.	1.3	20
9	Phase II clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky mass. <i>International Journal of Clinical Oncology</i> , 2016, 21, 1120-1127.	2.2	17
10	An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023. <i>BMC Cancer</i> , 2018, 18, 771.	2.6	17
11	Efficacy and safety of standard of care with/without bevacizumab for platinum-resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023. <i>Cancer Science</i> , 2022, 113, 240-250.	3.9	17
12	Phase II Clinical Study of the Combination Chemotherapy Regimen of Irinotecan Plus Oral Etoposide for the Treatment of Recurrent Ovarian Cancer (Tohoku Gynecologic Cancer Unit 101 Group Study). <i>International Journal of Gynecological Cancer</i> , 2011, 21, 44-50.	2.5	16
13	Phase II study of tri-weekly cisplatin and irinotecan as neoadjuvant chemotherapy for locally advanced cervical cancer. <i>Oncology Letters</i> , 2010, 1, 515-519.	1.8	14
14	Case of peptide-producing strumal carcinoid of the ovary: A case report and review. <i>Journal of Obstetrics and Gynaecology Research</i> , 2012, 38, 1266-1270.	1.3	13
15	A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup) <i>Tj ETQq1 1 0.784314 rg51 /Overl</i>	2.4	11
16	Tako-Tsubo Cardiomyopathy Caused Immediately following Cesarean Section Delivery of Triplets: A Case Report. <i>Gynecologic and Obstetric Investigation</i> , 2012, 74, 84-88.	1.6	10
17	A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study). <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 895-901.	2.3	9
18	A New Therapeutic Strategy for Recurrent Ovarian Cancer—Bevacizumab beyond Progressive Disease. <i>Healthcare (Switzerland)</i> , 2019, 7, 109.	2.0	8

#	ARTICLE	IF	CITATIONS
19	Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report. <i>OncoTargets and Therapy</i> , 2014, 7, 165.	2.0	7
20	Comparative Cytogenetic Studies of Benign, Borderline, and Malignant Epithelial Ovarian Tumors. <i>Journal of Obstetrics and Gynaecology Research</i> , 1996, 22, 541-549.	1.3	6
21	A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study). <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 355-361.	2.3	6
22	Are platinum agents, paclitaxel and irinotecan effective for clear cell carcinoma of the ovary? DNA damage detected with $^3\text{H}2\text{AX}$ induced by anticancer agents. <i>Journal of Ovarian Research</i> , 2012, 5, 16.	3.0	5
23	A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcinoma of the uterine cervix. <i>International Journal of Clinical Oncology</i> , 2014, 19, 336-340.	2.2	5
24	A case of ovarian adenosquamous carcinoma arising from endometrioid adenocarcinoma: a case report and systematic review. <i>Journal of Ovarian Research</i> , 2016, 9, 48.	3.0	5
25	Expectations and Challenges of First-Line Maintenance Therapy for Advanced Ovarian Cancer. <i>Medicina (Lithuania)</i> , 2021, 57, 501.	2.0	5
26	Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A1^*6 and UGT1A1^*28 presenting with serious adverse events during irinotecan hydrochloride/nedaplatin therapy. <i>Journal of Obstetrics and Gynaecology Research</i> , 2013, 39, 1354-1358.	1.3	4
27	Docetaxel and carboplatin chemotherapy for treating patients with stage IVB or recurrent non-squamous cell carcinoma of the uterine cervix: a phase II study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1314-1321.	2.2	4
28	Neoadjuvant Chemotherapy Using Platinum-Based Regimens for Stage Ib2-II Squamous Cell Carcinoma and Non-Squamous Cell Carcinoma of the Cervix. , 2012, , .		3
29	A Case of Fallopian Tube Adenofibroma: Difficulties Associated with Differentiation from Ectopic Pregnancy. <i>Clinical Medicine Insights: Case Reports</i> , 2014, 7, CCRp.S18859.	0.7	3
30	A case of primary ovarian signet-ring cell carcinoma treated with S-1/CDDP therapy. <i>Journal of Ovarian Research</i> , 2020, 13, 33.	3.0	3
31	Advanced squamous cell carcinomas arising from mature cystic teratoma of the ovary: a retrospective case series at the Tohoku Gynecologic Cancer Unit. <i>International Cancer Conference Journal</i> , 2016, 5, 146-149.	0.5	2
32	Adjuvant Chemotherapy for Endometrial Cancer (ACE) trial: A randomized phase II study for advanced endometrial carcinoma. <i>Cancer Science</i> , 2022, , .	3.9	2
33	Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas. <i>Cancers</i> , 2021, 13, 6120.	3.7	2
34	Neoadjuvant chemotherapy of docetaxel and carboplatin in patients with stage Ib2 to IIb nonsquamous cervix cancer of the uterus.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5103-5103.	1.6	1
35	Primary ovarian serous psammocarcinoma-a case report with mini literature review. <i>Obstetrics & Gynecology International Journal</i> , 2020, 11, 192-195.	0.1	1
36	Identifying Prognostic Factors in Japanese Women with Pseudomyxoma Peritonei: A Retrospective Clinico-Pathological Study of the Tohoku Gynecologic Cancer Unit. <i>Tohoku Journal of Experimental Medicine</i> , 2011, 224, 161.	1.2	0

#	ARTICLE	IF	CITATIONS
37	Analysis of the antitumor activity of gemcitabine and carboplatin against ovarian clear-cell carcinoma using the DNA damage marker γ -H2AX. <i>OncoTargets and Therapy</i> , 2013, 6, 901.	2.0	0
38	A recurrent ovarian cancer patient with a history of nine prior chemotherapy regimens who was safely treated with weekly paclitaxel plus bevacizumab and achieved a complete response: a case report. <i>OncoTargets and Therapy</i> , 2015, 8, 2097.	2.0	0
39	Comparison of Postoperative Adjuvant Chemotherapy and Concurrent Chemoradiotherapy for FIGO2018 Stage III C1 Cervical Cancer: A Retrospective Study. <i>Medicina (Lithuania)</i> , 2021, 57, 548.	2.0	0